Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Predicting outcomes in RCC using cell cycle progression score

Jeff Tosoian • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Prostate Cancer

Jeff Tosoian, MD, MPH, Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, discusses the use of cell cycle progression (CCP) score to risk stratify prostate cancer. The CCP score could also predict the likelihood of cancer recurrence in renal cell cancer (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Jeff Tosoian

Prostate active surveillance
Jeff Tosoian • 15 Feb 2020

Related Videos

1:10
Treatment options for patients with metastatic castration-resistant prostate cancer
Christos Kyriakopoulos • 2 Jun 2024
0:40
Neoadjuvant sacituzumab govitecan for muscle-invasive bladder cancer
Antonio Cigliola • 3 Jun 2024
0:47
Role of predictive biomarkers in patients with MIBC
Antonio Cigliola • 3 Jun 2024
1:25
SURE-01/02: sacituzumab govitecan and pembrolizumab for MIBC
Antonio Cigliola • 3 Jun 2024
The content of VJOncology is intended for healthcare professionals